©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2023; 29(48): 6235-6238
Published online Dec 28, 2023. doi: 10.3748/wjg.v29.i48.6235
Published online Dec 28, 2023. doi: 10.3748/wjg.v29.i48.6235
Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1
Yue-Hua Yin, Bing Chang, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Li-Xuan Sang, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China
Author contributions: Yin YH, Sang LX and Chang B wrote this letter.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Bing Chang, Chief Physician, Postdoc, Professor, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. cb000216@163.com
Received: October 7, 2023
Peer-review started: October 7, 2023
First decision: October 23, 2023
Revised: November 8, 2023
Accepted: December 6, 2023
Article in press: December 6, 2023
Published online: December 28, 2023
Processing time: 81 Days and 3.3 Hours
Peer-review started: October 7, 2023
First decision: October 23, 2023
Revised: November 8, 2023
Accepted: December 6, 2023
Article in press: December 6, 2023
Published online: December 28, 2023
Processing time: 81 Days and 3.3 Hours
Core Tip
Core Tip: Semaglutide is effective and safe for nonalcoholic fatty liver disease (NAFLD) but does not improve fibrosis. The treatment of NAFLD requires further combinations of drugs with different and complementary mechanisms of action.